Background To inform plans to achieve universal health coverage (UHC), we estimated utilisation and unit cost of outpatient visits and inpatient admissions, did a decomposition analysis of utilisation, and estimated additional services and funds needed to meet a UHC standard for utilisation.
Introduction
Universal health coverage (UHC) is a global priority. It is one of three strategic priorities of WHO's General Programme of Work for 2019-23. 1 It is also target 3.8 of the Sustainable Development Goals aimed at achieving "financial risk protection, access to quality essential health-care services, and access to safe, effective, quality and affordable essential medicines and vaccines for all". Meeting the target will require improvements in population-level interventions, and personal health services to promote health and provide preventive and curative care. 2 Indicator 3.8.1 on coverage of essential health services and indicator 3.8.2 on financial risk protection will monitor progress towards the target. Researchers have proposed indices of essential health service coverage. 3, 4 The 2016 Sustainable Development Goal Collaborators for the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) calculated a UHC index of personal health services with 41 items, including coverage of nine tracer interventions and mortality from 32 causes that are amenable to care. 3 The items represented essential services such as reproductive, maternal, newborn, and child health care, and access to care for infectious diseases, non-communicable diseases, and injuries. More research is needed, however, on utilisation and unit costs of personal health services in the health systems that will expand coverage over the next 12 years.
Although previous researchers have reported on utilisation for multiple countries, none reported on all countries over time. The Organisation of Economic Cooperation and Development (OECD) reports the annual number of outpatient visits per person and inpatient discharges for 35 member countries (with the exception of inpatient admissions for Canada and the USA), and five non-member countries for selected years. The probabilities of having general practitioner and specialist doctor visits in the past year were estimated for 18 OECD countries using the European Health Interview Survey or the most recent national health survey. 5 The number of outpatient visits in the past 4 weeks and inpatient admissions in the past year were estimated for 39 countries outside of OECD using World Health Survey data. 6 Systematic estimates have not been reported for more than half of countries globally, most of which have low scores on the UHC indices.
WHO's Choosing Interventions that are Cost-Effective (WHO-CHOICE) researchers estimated unit costs of outpatient visits and inpatient bed-days for 191 countries in 2007 and 2008 using facility-level data from 30 countries. 7 Although the WHO-CHOICE estimates were standardised to reflect health systems performing at high levels of efficiency, they have been used extensively in cost-effectiveness analyses when more exact micro-costing estimates were neither practical nor appropriate. 8, 9 The estimates are due for an update, based on nationally representative samples, and bounded by a national health expenditure envelope.
The aim of this study was to support progress towards UHC. The objectives were to produce global estimates of outpatient visits and inpatient admissions by age and sex for 27 years and unit costs for these services for 22 years, and to demonstrate two applications of the estimates to inform expansion of coverage of essential personal health services. We decomposed changes in volume of services by location from 1990 to 2016 into 
Research in context
Evidence before this study Prospects of expanding access to quality essential health services are improving, as WHO seeks to expand health coverage to 1 billion people by 2023 and countries prepare to meet this target of the Sustainable Development Goals by 2030. Researchers have made progress towards measuring universal health coverage (UHC), but far less is known about the utilisation and unit cost of services of health systems that will expand coverage. We searched the PubMed database on July 3, 2017, for utilisation estimates with the Medical Subject Heading term "global health" and terms for health-care outputs such as "ambulatory care" and "inpatient" as well as the websites for the Organisation of Economic Co-operation and Development, World Bank, and WHO with no date or language restrictions. Utilisation of outpatient visits and inpatient admissions has not been estimated globally, and existing global estimates of unit costs are 10 years old. Researchers have used different methods to estimate the cost of UHC for selected countries only (ie, not globally), and the additional services needed have not been quantified.
Added value of this study
We generated a time series of global health-care utilisation, and updated unit cost estimates. We also quantified the volume of services needed to expand access for a given population, and the costs to supply those services. Building on the strengths of methods from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) that account for age, sex, spatial, and temporal patterns in health outcomes, and adjusting for differences across heterogeneous data sources, we produced estimates of utilisation per person for visits and admissions by age and sex for 195 countries from 1990 to 2016. We also decomposed changes in the volume of services over time into changes in population size, age and sex structure, and utilisation rates for every location. We estimated the share of total health expenditure on each service using mutually exclusive and collectively exhaustive National Health Account data and the cost per outpatient visit and per inpatient admission for 188 countries from 1995 to 2016. Our macro-costing approach reflected current expenditures and efficiency. We also created UHC standards of utilisation per disability-adjusted life-year based on existing health systems rather than ideals to estimate the additional services and funding needed annually to expand health coverage in 2016 for 188 countries, with results similar to previous research using different methods and groups of countries.
Implications of all the available evidence
Globally, outpatient visits have increased by more than half and inpatient admissions have increased by more than two-thirds since 1990. In countries such as China, Indonesia, Thailand, and Turkey, policies to expand coverage are associated with increased utilisation rates. Meanwhile, in several countries in the sub-Saharan Africa super-region with low scores on the GBD's UHC index of personal health services, most of the increases in volume of services have been from population growth rather than increases in utilisation rates. Using the Netherlands as a UHC standard, although both primary and specialty services are essential, the gap in services that countries must overcome to achieve UHC is larger for admissions than for visits. We also identified intermediate UHC standards for utilisation, such as Portugal, for which a smaller increase in admissions would expand coverage initially as a step towards achieving UHC in the future.
changes in utilisation rates, population size, and age and sex structure of the population to show the role of each factor in every country over time. We estimated the services and funding needed to expand utilisation for the 2016 population size and structure to meet a UHC standard for utilisation per disability-adjusted life-year (DALY) using counterfactual DALY estimates from GBD 2016.
Methods

Definition of utilisation
We defined outpatient utilisation rate as the annual number of visits per capita to a health facility that did not result in admission and defined inpatient utilisation rate as the annual number of admissions per capita for one night or more into a health facility. We included preventive, rehabilitative, and curative care, and adhered as closely as possible to the International Classification for Health Accounts' categories for Health-Care Functions (HC) so that the utilisation rate would be consistent with expenditure data based on the System of Health Accounts 2011. 10 For outpatient visits, our definition mapped to four categories: outpatient curative (HC 1.3) and rehabilitative (HC 2.3) care, facility-based preventive maternal and child care (HC 6.4), and vaccinations (HC 6.2). For inpatient admissions, our definition mapped to two categories: inpatient curative (HC 1.1) and rehabilitative (HC 2.1) care. Our estimates excluded day-patient admissions (HC 1.2 and HC 2.2), and long-term care (HC 3) because data on their utilisation and expenditures were not available globally.
Data sources for utilisation estimates
We compiled data sources from a systematic review of surveys and administrative data within the Global Health Data Exchange. All data sources were nationally or subnationally representative. In compliance with the Guidelines for Accurate and Transparent Health Estimates Reporting, 11 we documented the methods of the systematic review, data sources for each country, data processing, and estimation (appendix p 6).
We compiled outpatient utilisation data from 130 countries, spanning 1175 country-years, and inpatient data from 128 unique countries, spanning 2068 countryyears (appendix p 11). Administrative sources contributed 59·1% of outpatient country-years and 80·3% of inpatient country-years. More data were available from administrative records in the high-income and central Europe, eastern Europe, and central Asia super-regions due to Map displays the age-standardised estimated annual number of outpatient visits per capita in 2016 for all ages and both sexes combined. The rate ranged from 2·5 to 7·0 visits per person for the majority of countries, and the key shows 0·5 visit increments in this range to present differences among these countries. ATG=Antigua 
Methods for utilisation estimates
The unit of analysis was average utilisation by sex and age categories, where the 23 age categories were early neonatal (0-6 days), neonatal (7-27 days), infants (28-364 days), 1-4 years, followed by 5-year intervals from 5-9 years to 90-94 years, and finally 95 years or older. We estimated the age-sex-specific rates of utilisation for visits and admissions with DisMod-MR, version 2.1. DisMod-MR is a Bayesian hierarchical metaregression method and an established method to estimate age-sex-specific incidence and prevalence rates of diseases by location and year. 12, 13 Measures of utilisation and recall periods were not consistent across surveys (appendix p 19), and we used two methods to adjust for inconsistencies. When inconsistencies across data sources did not differ by age category, we included dichotomous covariates in the DisMod-MR models. The reference category was annually reported, administrative records from either national sources or facility-level health information system data. For the outpatient utilisation model, we created four covariates for recall periods and two for inconsistent phrasing of the utilisation questions. For the inpatient utilisation model, we created two covariates for survey series such as the World Health Survey. When inconsistencies differed by age category such as 1-year recall of inpatient admissions, we used age-spline regressions to adjust for the differences before estimating the DisMod-MR models (appendix pp [23] [24] [25] [26] [27] .
Additional covariates were the Socio-demographic Index-a summary development indicator of income per capita, years of schooling, and total fertility rate-in the outpatient model and hospital beds per 1000 popu lation in the inpatient model. The rationale for including each covariate, their definitions, and estimated coefficients are reported in the appendix (pp [28] [29] . To account for geographical variation, we used random effects to nest GBD super-regions, regions, and countries (appendix pp 13-18).
Decomposition of changes in utilisation
The total volume of outpatient visits and inpatient admissions was calculated by multiplying age-sexspecific utilisation rates for each location by the population for each category sourced from GBD 2016 national estimates.
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decomposed changes in total volume of services from 1990 to 2016 into changes in four factors: utilisation rates by age and sex, population growth, population ageing, and sex composition. Decomposition of these factors followed the method in Das Gupta 15 to estimate the average marginal effect of changing one factor across all combinations of changes in the other factors.
Unit cost estimates
We estimated unit costs as expenditure per capita on each service divided by utilisation per capita. Expenditure per capita was the product of total health expenditures (THE) per capita in 2017 international dollars and the share of outpatient services in THE for visits or share of inpatient services for admissions. THE estimates 16 from 1995 to 2015 and projections for 2016 17 were available for 188 countries. The shares were estimated with 795 country-years of National Health Accounts data, which provided a mutually exclusive and collectively exhaustive account of the flow of THE through a health system (appendix pp 51-52). The sample represented 105 (56%) of 188 countries but fewer than half of the countries in three super-regions: southeast Asia, east Asia, and Oceania; Latin America and the Caribbean; and north Africa and the Middle East. Outpatient spending was estimated as the share of outpatient curative (HC 1.3) and rehabilitative (HC 2.3) care and inpatient spending was estimated as the share of inpatient curative (HC 1.1) and rehabilitative (HC 2.1) care.
Cost estimates to meet a UHC standard for utilisation
We estimated the additional services and funds needed to meet a UHC standard for utilisation. The metric for the units of service was the 2016 volume of services per DALY, using a counterfactual estimate of a DALY based on GBD 2016 data. A country's 2016 burden of disease was endogenous to its current health service utilisation, meaning that improved access and quality of services affected the burden. We standardised the burden of disease across countries by removing the effects of access and quality of services using age-specific estimates of the GBD 2016 Healthcare Access and Quality (HAQ) index. 18 We regressed 2016 DALYs for each age and sex category on the Socio-demographic Index and HAQ index; we predicted the counterfactual DALYs by setting the HAQ index to zero and thus removing the effects of access and quality (appendix pp 61-63).
Our UHC standard for utilisation-ie, services per counterfactual DALY-was based on an existing health system rather than an ideal. For each country, we calculated the additional units of service needed to meet the UHC standard and multiplied the total by the unit cost of service in that country. Units of service needed was the difference between the standard for each age-sex combination and the country's 2016 volume per counterfactual DALY for that age-sex combination; this was then multiplied by those DALYs to obtain an estimate given in units of service. The national total was the sum of units of service across age-sex categories.
To identify the UHC standard for utilisation, we set each country in turn as the standard and calculated the global cost to reach that standard (see appendix p 71 for the 188 global estimates). Several countries formed a frontier, with high value on the GBD 2016 UHC index and lowest global cost for their value. Among countries on the frontier, we selected one from each of the top two quintiles of the Socio-demographic Index to serve as standards: from the first quintile we chose the Netherlands, ranked ninth on the UHC index, as the standard for the main analysis and from the second quintile we chose Portugal, ranked 34th on the UHC index, as an intermediate UHC standard for a sensitivity analysis. The aggregate ratio of total volume to counterfactual DALYs was 7·25 for visits and 0·17 for admissions for the Netherlands (see appendix pp 74-75 for the age-sex-specific ratios that were the standards used to calculate units of service needed) and 7·01 for visits and 0·14 for admissions for Portugal. Health systems differed in the quality and type of services they provided, as well as in the volume of services. We estimated that the unit costs in the Netherlands were 28% higher for visits than predicted by cost-of-living differences in gross domestic product per capita and 24% higher for admissions (appendix p 85). We did a sensitivity analysis with unit costs increased by these percentages as a measure of improvements.
Uncertainty
We captured and propagated uncertainty in the analysis, including all three steps of the utilisation estimates: sampling uncertainty from extracted data, uncertainty from adjustments to inconsistently reported data, and uncertainty estimated as part of DisMod-MR. For all reported estimates, we took 1000 draws from the posterior distributions. The mean of the 1000 draws was the point estimate and the 2·5th and 97·5th percentile of the draws defined the uncertainty interval (UI). Applications using modelled outputs were done at the draw level.
Role of the funding source
The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had complete access to all the data in the study and had final responsibility for the decision to submit for publication.
Results
The global age-standardised utilisation rates were 5·42 outpatient visits (95% UI 4·88-5·98) and 0·10 inpatient admissions (0·09-0·11) per capita in 2016.
The age-standardised utilisation rate for outpatient visits was highest in the high-income Asia-Pacific (15·46, 95% UI 14·02-17·06) and eastern European (10·29, 9·78-10·79) regions, and lowest in southern sub-Saharan Africa (3·53, 3·03-4·08) and the Caribbean (3·37, 2·89-3·88; figure 1 ; appendix pp 37-43). Taiwan (province of China) had the highest outpatient utilisation rate (19·61, 17·04-22·44) and Burkina Faso had the lowest (2·00, 1·17-2·32). The age-standardised utilisation rates for inpatient admissions were highest in the eastern Europe (0·23, 0·22-0·24) and central Europe (0·18, 0·17-0·20) regions and lowest in southeast Asia (0·03, 0·02-0·04) and eastern sub-Saharan Africa (0·05, 0·05-0·06; figure 2; appendix pp 44-50). Bulgaria had the highest inpatient utilisation rate (0·27, 0·26-0·28) and Cambodia had the lowest (0·02, 0·02-0·03). Many countries were exceptions to the regional patterns, and the range of estimates within some regions was broad. In western Europe where the age-standardised outpatient rate was 7·33 (95% UI 6·68-8·12), the rates were below the global average in Scandinavia, England, Greece, the Netherlands, and Portugal. In central Latin America where the outpatient rate was 4·60 (3·99-5·27), the rates were above the global average in Colombia, Nicaragua, and Panama. From 1990 to 2016, outpatient volume increased from 24·80 billion (95% UI 21·81-28·17) to 39·35 billion (35·38-43·58) visits globally. Of this 58·65% increase in visits, 42·95% was from population growth, 8·09% from population ageing, and 7·63% from increases in utilisation rates; small changes in the sex composition of the population (ie, if utilisation rates differ between the sexes) account for the difference between the total change from 1990 to 2016 and the sum of three factors reported here. Changes over time in the age-sex-specific outpatient utilisation rates increased volume in six super-regions (figure 3A), with the exception of the high-income region. Inpatient volume increased from 0·42 billion (0·38-0·47) to 0·71 billion (0·65-0·77) admissions. Of this 67·96% increase in admissions, 44·33% was from population growth, 9·99% from population ageing, and 13·55% from increases in utilisation rates. Changes in inpatient utilisation rates decreased volume in five super-regions, Changes in the volume of outpatient visits and inpatient admissions from 1990 to 2016 were decomposed into changes in four factors: age-sex-specific utilisation rates, total population, the share of the population in each age category, and the share of the population of each sex within each age category. The black dots represent the overall percentage change in volume of each service. Colours represent the percentage that each factor contributed to overall percentage change. Bars to the left of zero show that the factor contributed to a decrease and bars to the right show an increase. GBD=Global Burden of Diseases, Injuries, and Risk Factors Study. *UK data are an aggregate of the data from the four constituent countries displayed below. †Results extend off the scale. For east Asia, change due to age-sex utilisation rates is 357%, contributing to a total percentage change of 443%. For China, change due to age-sex utilisation rates is 404%, contributing to a total percentage change of 497%. Change due to age-sex-specific utilisation rates Change due to population ageing figure 3G ; inpatient results for China extend off the scale). The 114·41% increase in outpatient visits decomposed into a 69·13% increase from utilisation rates, 27·94% from population growth, and 17·26% from population ageing. The 497·00% increase in inpatient admissions decomposed into a 403·85% increase from utilisation rates, 59·80% from population growth, and 32·73% from population ageing. Increases in age-sex-specific utilisation rates also accounted for large increases in outpatient visits in Thailand (19·44% of a 63·85% increase; figure 3G ) and inpatient admissions in Indonesia (62·35 % of a 141·01% increase; figure 3G ) and Turkey (202·22% of a 302·87% increase; figure 3E ). Central Europe, eastern Europe, and central Asia was the only super-region with a decrease, albeit small, in the volume of inpatient admissions ( figure 3B ). In the central Asia region, the 9·00% decrease in inpatient admissions decomposed into a 35·30% decrease from utilisation rates, offset by a 24·24% increase from population growth and 2·00% increase from population ageing. In eastern Europe, the 7·96% decrease in inpatient admissions decomposed into a 4·40% decrease from utilisation rates and 4·44% from population decline, offset by a 0·66% increase from population ageing.
In 2016, the cost per outpatient visit (in 2017 international dollars [I$]) ranged from I$2 (in Burundi, Eritrea, and Central African Republic) to I$478 (USA; table). The cost per inpatient admission ranged from I$87 (Central African Republic) to I$22 543 (USA; table). Unit cost estimates generally followed patterns of THE per capita. Spearman rank correlation coefficients for THE per capita were 0·93 for outpatient costs and 0·89 for inpatient costs. Correlation coefficients for share of expenditure were 0·39 for outpatient costs and 0·67 for inpatient costs whereas those for utilisation per capita were 0·26 for outpatient costs and 0·25 for inpatient costs.
We compared our unit cost estimates to the WHO-CHOICE estimates in 2008, the year of their most recent estimates. Our estimates were generally higher (figure 4); cost per outpatient visit at any health facility was 102·67% higher on average than the WHO-CHOICE estimates for secondary hospitals, and cost per admission to any hospital was 2·64% higher on average than WHO-CHOICE estimates for teaching hospitals (appendix p 53).
Globally, 10·42 billion (95% UI 7·81-12·74) additional outpatient visits per year in 161 countries at a cost of (in 2017 I$) I$361·84 billion (212·28-526·66) were needed in 2016 to meet the UHC standard for utilisation, and 0·35 billion (0·31-0·38) additional inpatient admissions were needed in 184 countries at a cost of I$815·85 billion (583·87-1056·03), leading to a total additional cost of I$1177·69 billion (896·05-1456·56). The global gap in inpatient services was larger than in outpatient services, with a 49·20% increase required in admissions and a 26·57% increase required in visits to meet the UHC standard. This additional cost of each service for specific countries can be calculated with the results for unit cost and additional services in the table; note that the cost of scaling up to the UHC utilisation standard was done at the age-sex level, leading some countries to have a cost of UHC scale-up greater than zero despite their aggregate utilisation per counterfactual DALY being greater than the standard set by the Netherlands. Of the total additional cost required to reach the UHC standard, lowincome countries required 4·00% (I$47·09 billion, 95% UI 37·38-56·08), lower-middle countries required 38·72% (I$456·04 billion, 365·53-550·89), upper-middle income countries required 34·67% (I$408·36 billion, 314·28-500·04), and high-income countries required 22·60% (I$266·21 billion, 152·21-380·71).
Four of 21 regions each accounted for 10% or more of the additional cost of reaching the UHC standard for In sensitivity analyses using Portugal as an intermediate UHC standard for utilisation, the additional cost to meet this standard was 63·31% (I$745·58 billion, 95% UI 556·42-932·09) of the full standard (appendix pp 86-92). Under the intermediate UHC standard, the gap in admissions was 32·97% (0·23 billion of 0·71 billion admissions) and the gap in visits was 19·51% (7·67 billion of 39·35 billion visits; appendix pp 86-92). When adjusting for quality and types of service, the cost to reach the full standard increased by 25·23% to I$1474·81 billion (95% UI 1120·78-1824·45), with higher unit costs to reflect the cost of these improvements in the Netherlands (appendix pp 93-99).
Discussion
We have reported the first global estimates of utilisation of outpatient visits and inpatient admissions, and unit costs for these services where the cost estimates were based on expenditures from the National Health Accounts. In our decomposition analysis, we have highlighted examples of countries with substantial changes in utilisation rates and have shown results for countries where increased volume was driven by population growth. Using the population and age structure in 2016, we have estimated the additional services and funds needed to meet a UHC standard for utilisation.
The decomposition analysis captures the effects of known trends in UHC, as well as other changes in health systems since 1990. China's increase in visits and admissions due to changes in utilisation rates was consistent with the expansion of insurance coverage to hospital services in 2003 and comprehensive care in 2008. 19 Similarly, the increase in admissions in Indonesia due to changes in utilisation rates was consistent with a social security law in 2004 that included national health coverage. 20 Although Indonesia's comprehensive health insurance scheme was not finalised until 2014, coverage of inpatient services expanded for some populations beginning in 2003. The increase in visits in Thailand due to changes in the utilisation rates was consistent with their UHC scheme that extended coverage in 2002 to the 30% of population who previously were uninsured. 21 The increase in services in Turkey reflected the additional primary health-care teams and hospital beds from their Health Transformation Program. 22 Agesex-specific inpatient utilisation rates decreased in 21 The unit cost results for 188 countries were higher than the upper range of the widely referenced WHO-CHOICE estimates in 2008. 7 The WHO-CHOICE researchers estimated cost functions with available unit cost estimates from 30 countries, where the unit of analysis was a facilityyear. 7 Our expenditure estimates included ancillary services such as diagnostic exams and medical supplies such as drugs provided during the visit or admission, consistent with the National Health Account categories, 10 whereas the WHO-CHOICE estimates excluded them. Our unit costs estimates used utilisation as the denominator and reflected current efficiency. The WHO-CHOICE researchers sought to compare inter ventions across WHO locations and countries at a standard level of efficiency where all facilities operated at the 80th percentile of measured capacity. In the absence of estimates of actual unit costs, however, many researchers have relied on the WHO-CHOICE estimates as if they represented actual health systems, and thus have underestimated the cost of treatment interventions and the cost savings from preventive interventions in most countries. 8, 9 Health facilities in Kenya, Uganda, and Zambia operated at 40% of capacity or less during 5-year periods that differed across countries, but were all between 2006 and 2011. 24 To our knowledge, only two other studies have estimated comprehensive unit costs at the national level. Our unit cost estimates were macro-costing estimates, which the second US Panel on Cost-Effectiveness and Medicine referred to as "gross costing". 27 Approaches to estimating unit costs ranged from our unit costs per visit and admission to micro-costing estimates that directly enumerate and cost every input, and neither approach is always more accurate or precise. The Panel recommended the macro-costing approach for some analyses because of its "simplicity, practicality, and if data are obtained broadly, robustness to geographic, institutional, and other sources of variation". 30 For example, a macro-costing estimate might be appropriate for an intervention that changed the quantity of services 8, 9 or when its effect on the cost of services was known. Our macro-costing estimates were average costs, which would be the same as the marginal costs in stable health systems. Average costs can be less than marginal costs when initiating interventions or serving remote locations or populations. Researchers should consider the nature of the interventions, locations, and populations in their analyses and adjust the average costs as appropriate. Macro-costing estimates can be adjusted for specific diagnoses, using a country's weights for service intensity or other representative weights. 28 The total cost of meeting a UHC standard for utilisation was 2017 I$1177·69 billion or 2017 US$575·57 billion and similar to previous UHC cost estimates for the same countries, 29, 30 but our methods differed. Stenberg and colleagues 29 estimated that progress towards UHC in 67 low-income and middle-income countries would cost 2017 US$287 billion per year by 2030 and I$391 billion for their ambitious scenario with 95% coverage of a full package of services. Our total cost for the same 67 countries was 2017 US$297·39 billion in 2016. Stenberg and colleagues used benchmarks such as the numbers of facilities and laboratories per person and human resource targets to estimate the cost of platforms, rather than the WHO-CHOICE unit costs, and added the commodity costs for 187 interventions. Jamison and colleagues 30 estimated that a high priority package of interventions in 83 low-income and lower-middle income countries would cost 2017 US$113 billion in 2015 and US$223 billion for essential UHC. Our total cost for the same 83 countries was 2017 US$158·10 billion in 2016. Jamison and colleagues produced unit cost estimates for 218 interventions, using the best unit cost estimates in the literature with adjustments for health professional salaries across countries. Both previous estimates included the cost of population and community platforms, which they found to be 15% 29 and 13-19% 30 of total cost. Our estimates of the additional cost of personal health services did not include these platforms.
We report the first estimate of the additional services needed to meet a UHC standard. Equally important, our metric of utilisation per counterfactual DALY made it possible to compare health systems with different combinations of visits and admissions. Unlike diseases where zero burden is the goal, we needed to identify a goal for health services. There is both overutilisation and underutilisation of services. Some care can be provided as an outpatient or as an inpatient, with the latter being more expensive. For example, the burden could be reduced with several visits to screen for a disease and provide timely treatment, or it could be reduced with an admission for severe illness. Our frontier analysis explored different combinations of visits and admissions at the level of the health system rather than the intervention. We identified countries such as the Netherlands and Portugal whose combination achieved high values on GBD's UHC index at lower costs than for other combinations. In our sensitivity analysis using Portugal as the standard, it provided an intermediate UHC standard requiring relatively fewer admissions.
Our UHC cost estimate was based on additional services at the current quality and type of service, and was 25·23% higher in the sensitivity analysis with higher unit costs to reflect improvements, similar to the additional cost of commodities in previous estimates. 29 Like previous estimates, ours was the starting point for national assessments that would benefit from countryspecific information; quality improvement would be sub stantially more in some countries and minimal in others. When improvements in the quality of essential personal health services are delivered during visits and admissions, the additional cost of diagnostic exams and medical goods would be calculated using data on the country's burden of disease, current purchases, and lowest available prices, and then added to total expenditure for a service to calculate a country-specific estimate of higher unit costs.
To put our estimates in perspective, we used Dieleman and colleagues' estimate of pooled resources for health, 17 which were prepaid revenues through government financing, social health insurance, private insurance, or development assistance for health. Pooled resources were THE minus out-of-pocket spending. In 2017 international dollars, the additional cost of reaching the UHC standard for utilisation in 2016 was 105·97% (I$71 of I$67 per capita) of pooled resources for lowincome countries, 129·66% (I$153 of I$118 per capita) for lower-middle-income countries, 23·59% (I$159 of I$674 per capita) for upper-middle-income countries, and 4·66% (I$227 of I$4876 per capita) for high-income countries. As Dieleman and colleagues reported, some expansion of coverage in low-income and lower-middleincome countries might be possible with improvements in efficiency as well as additional funds.
Going forwards, health systems need to expand to accommodate population growth and ageing at the same time that they expand coverage. Population growth accounted for most of the increase in the volume of services from 1990 to 2016 globally and among four super-regions where the GBD's UHC index in many countries was low: Latin America and the Caribbean, north Africa and the Middle East, south Asia, and sub-Saharan Africa. Our cost of meeting a UHC standard for utilisation was based on population in 2016 but future estimates could include the additional cost associated with population growth and ageing.
Our methods for estimating utilisation and unit costs lend themselves to calculating the costs of future changes in health policy such as expansion in coverage. Utilisation could be forecast with global projections of population growth and age structure 31 and forecasts of the Sociodemographic Index, 32 which are available, as well as hospital capacity. Our analysis from 1990 to 2016 showed that hospital capacity was relatively stable over time in the absence of changes in health policy and could be forecast. Health expenditures on services could be forecast with available forecasts of THE and gross domestic product per capita 17 and the share of expenditures on each service. Again, the shares were relatively stable and could be forecast. Estimates of the costs of changes in health policy would be modelled in this context. This study had several limitations. A major limitation was the availability, quality, and scope of the data. Our systematic search for utilisation data revealed gaps, particularly before the year 2000 in countries outside of the high-income and central Europe, eastern Europe, and central Asia super-regions. Furthermore, the data sources for the other super-regions were primarily surveys and utilisation questionnaires were not standardised. Despite these gaps, 330 of 1175 country-years of outpatient data and 275 of 2068 country-years of inpatient data were from countries in the other super-regions, and our estimates adjusted for inconsistencies across questionnaires. In countries that continue to rely on surveys, it is important to standardise utilisation questions, as well as collect additional data (appendix p 10). A further limitation is that some of the decrease in inpatient admissions in the highincome super-region might have been associated with an increase in day hospital admissions, but these services were not included in our analysis. Utilisation and expenditure data for these services were not generally available, even though day curative (HC 1.2) and rehabilitative care (HC 2.2) were categories of the System of Health Accounts. Finally, although the utilisation estimates included facility-based preventive maternal and child care (HC 6.4), and vaccinations (HC 6.2), the expenditure shares did not because they were not reported in 649 (81·6%) of 795 of National Health Accounts. Their omission might have underestimated the unit cost of outpatient visits but the effects would have been substantial for only 16 country-years in which these categories exceeded 3% of THE.
In conclusion, plans to expand health coverage can be based on utilisation and unit costs of current health systems and guided by standards of utilisation of outpatient visits and inpatient admissions that achieve the highest coverage of personal health services at the lowest cost. Estimates of the additional services needed should direct attention towards growth of health systems in the future, and complement available research on the interventions that should be covered and their cost.
